Immuron Ltd ADR (NQ: IMRN )
Press Releases about Immuron Ltd ADR
Immuron Travelan® continued strong sales growth
October 15, 2024
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
September 05, 2024
Immuron Board Changes
May 31, 2024
Immuron Director Resignation
May 03, 2024
Immuron to host Live Virtual Event
April 15, 2024
Immuron Travelan® sales continued strong growth
April 10, 2024
Immuron Presentation Australian Biologics Festival 2024
February 21, 2024
Immuron achieves record Travelan® sales
February 13, 2024
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
February 08, 2024
Immuron achieves record half yearly Travelan® sales
January 16, 2024
Immuron Clinical Trials Update
December 22, 2023
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
November 28, 2023
Immuron CEO Steven Lydeamore Investor Webinar Presentation
November 13, 2023
Immuron CEO Steven Lydeamore presented at AusBioInvest
October 30, 2023
Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023
Immuron achieves record quarterly Travelan® sales
October 11, 2023
Immuron achieves record monthly Travelan® sales
September 13, 2023
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|